These findings indicated that CpG-ODN treatment might downregulate IL-33/ST2, thereby reducing the expression of TSLP, inhibiting the TSLP-DC pathway, alleviating Th2/Th17 inflammatory response in smoke-related asthma, and reducing the degree of airway inflammatory cell infiltration and remodeling. This evidence concerns the gene IL33 and asthma.